BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) SVP Chan Henry Lee Sells 422 Shares

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) SVP Chan Henry Lee sold 422 shares of BeOne Medicines stock in a transaction on Monday, June 16th. The stock was sold at an average price of $266.50, for a total transaction of $112,463.00. The sale was disclosed in a document filed with the SEC, which is available at this link.

Chan Henry Lee also recently made the following trade(s):

• On Friday, June 6th, Chan Henry Lee sold 700 shares of BeOne Medicines stock. The shares were sold at an average price of $256.11, for a total transaction of $179,277.00.

BeOne Medicines Price Performance

Shares of ONC stock traded down $1.31 during trading hours on Wednesday, reaching $252.78. 230,404 shares of the company's stock were exchanged, compared to its average volume of 447,787. The firm has a market cap of $27.69 billion, a P/E ratio of -67.95 and a beta of 0.30. The business's 50 day simple moving average is $243.44. BeOne Medicines Ltd. - Sponsored ADR has a 1 year low of $141.31 and a 1 year high of $287.88. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.71 and a current ratio of 1.96.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $1.22 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.71) by $1.93. The business had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.12 billion. BeOne Medicines had a negative return on equity of 7.55% and a negative net margin of 9.40%. As a group, analysts predict that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. Wall Street Zen upgraded shares of BeOne Medicines from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. Royal Bank Of Canada dropped their price objective on shares of BeOne Medicines from $312.00 to $311.00 and set an "outperform" rating on the stock in a research note on Thursday, May 8th. Macquarie lifted their price objective on shares of BeOne Medicines from $259.00 to $313.00 and gave the company an "outperform" rating in a research note on Friday, February 28th. Bank of America upgraded shares of BeOne Medicines from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $207.00 to $320.00 in a research note on Monday, March 3rd. Finally, Sanford C. Bernstein set a $259.00 price objective on shares of BeOne Medicines in a research note on Thursday, March 13th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, BeOne Medicines presently has a consensus rating of "Buy" and a consensus target price of $319.00.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.